• Argos Therapeuticsof Durham, N.C. has began a Phase I/II trial to gauge the immunologic activity and safety of AGS-004 in HIV-infected adults. The study group will be 10 patients with durable viral suppression from highly active antiretroviral therapy. AGS-004 is a personalized RNA-loaded dendritic cell-based immunotherapy designed to stimulate the immune system to target and destroy the patient's unique viral burden. The primary study objective is to evaluate patient-specific anti-viral response following four doses over four weeks. Secondary trial objectives are to evaluate its safety, additional immune induction profiles, and the feasibility of production of AGS-004.
